← Back to Search

Other

Rose Geranium in Sesame Oil Nasal Spray for Nasal Vestibulitis

Phase 3

Waitlist Available

Led By Charles L Loprinzi

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 weeks after initiating the nasal spray

Awards & highlights

Study Summary

This trial compares rose geranium in sesame oil nasal spray to isotonic nasal saline in improving symptoms of nasal vestibulitis in cancer patients receiving chemotherapy.

Eligible Conditions

Nasal Vestibulitis
Cancer
Blood Cancers

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 2 weeks after initiating the nasal spray

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 2 weeks after initiating the nasal spray

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 2 weeks after initiating the nasal spray for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Response

Secondary outcome measures

Incidence of adverse events (AEs)

Palliative Care

Severity of most prominent nasal symptom indicated at baseline

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Arm A (rose geranium in sesame oil nasal spray)Experimental Treatment2 Interventions

Patients instill rose geranium in sesame oil nasal spray, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity.

Group II: Arm B (isotonic nasal saline)Placebo Group2 Interventions

Patients instill isotonic nasal saline, 1 spray in each nostril BID on days 1-14 in the absence of unacceptable toxicity. After 2 weeks, patients may instill rose geranium in sesame oil nasal spray as in Arm A for an additional 2 weeks in the absence of unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Rose Geranium in Sesame Oil Nasal Spray

2020

Completed Phase 3

~60

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor

3,206 Previous Clinical Trials

3,767,024 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,657 Previous Clinical Trials

40,933,608 Total Patients Enrolled

Charles L LoprinziPrincipal InvestigatorMayo Clinic in Rochester

3 Previous Clinical Trials

4 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA cleared Rose Geranium in Sesame Oil Nasal Spray for public use?

"Rose Geranium in Sesame Oil Nasal Spray is safe according to our team's 3-point scale. This product is in Phase 3 clinical trials, meaning that there is evidence of its efficacy as well as multiple rounds of data supporting its safety."

Answered by AI

Are there other instances where Rose Geranium in Sesame Oil Nasal Spray has been tested?

"Out of the 2 ongoing clinical trials investigating Rose Geranium in Sesame Oil Nasal Spray, 1 is in Phase 3. The many trials for this medication are primarily based in Grand Rapids, Minnesota, but there are a total of 34 locations running trials."

Answered by AI

Does this study have a large number of participants in different states?

"This trial currently has 33 patients, with recruitment locations including Sanford Cancer Center Worthington, Mayo Clinic Health System in Albert Lea, Essentia Health Virginia Clinic, and 30 other sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy

2020. "Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04620369.